Targeted Immunotherapy for Multiple Myeloma: Novel Mutant CCL27 Binders Targeting CCR10

Technology Description

Addressing the critical unmet need of resistance and relapse associated with current therapies, this innovative approach offers a powerful alternative to BCMA-targeted treatments. Our engineered CCL27 mutants exhibit significantly enhanced binding affinity to CCR10, enabling precise and effective targeting of cancer cells. Versatile in application, these binders can be utilized across a range of therapeutic platforms, including CAR T-cells and bispecific antibodies. Preclinical data demonstrates that mutant CCL27 CAR T cells exhibit superior cytotoxicity against multiple myeloma cell lines in vitro and significantly improved efficacy in vivo, outperforming BCMA-targeted therapies. This next-generation solution redefines possibilities for patients battling relapsed or resistant multiple myeloma.

Stage of Development

Pre-clinical proof of concept. 

Related Materials

• In vivo genome-wide CRISPR screens in human T cells to enhance T cell therapy for solid tumors - 09/24/2025